We await further updates then ,
Further updates will be provided as information is released by the relevant agencies.
All clinical data to date on DMX-200 demonstrates an exceptionally strong safety profile, with no serious adverse events related to the drug reported, and that the DMX-200 clinical benefit has outweighed any risks to date.
The positive signals suggest that treatment with DMX-200 may indeed result in clinically meaningful improvements in kidney function in FSGS patients.
I'm full to the gunnels...
Hope you have a relaxing weekend with friends and family , NZT
We await further updates then , Further updates will be provided...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
0.015(3.95%) |
Mkt cap ! $220.0M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 40.5¢ | 37.0¢ | $863.2K | 2.230M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 56796 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 15592 | 1 |
View Market Depth
| Last trade - 15.59pm 08/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |